You are here

amivantamab

J&J beats Tagrisso and Takeda to the punch in key NSCLC subset, picking up new FDA approval

Endpoints

Sun, 05/23/21 - 03:08 pm

non-small cell lung cancer

#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over

Endpoints

Thu, 05/20/21 - 12:21 pm

non-small cell lung cancer

JNJ's amivantamab puts more data behind the hype

EP Vantage

Tue, 02/2/21 - 11:11 pm

exon 20-insertion NSCLC

J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval

Endpoints

Thu, 01/28/21 - 11:16 pm

non-small cell lung cancer

Best-selling Tagrisso further outpaces an upcoming J&J rival, winning approval in new NSCLC indication

Endpoints

Mon, 12/21/20 - 10:59 am

non-small cell lung cancer

In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA

Fierce Biotech

Thu, 12/3/20 - 10:55 am

non-small cell lung cancer

metastatic non-small cell lung cancer